Network Pharmacology Analysis of Secondary Metabolites of Ciplukan (Physalis angulata L.) Against Lung Cancer
Open Access
- 10 June 2024
- journal article
- Published by Universitas Gadjah Mada in Majalah Farmaseutik
- Vol. 20 (2) , 282-291
Abstract
Lung cancer is the most common and high-risk type of cancer. Ciplukan (Physalis angulata L.) has antibacterial, anti-inflammatory, and anticancer activities, as well as cytotoxic ability and inhibits cancer cell growth. Research that discusses the molecular cellular mechanism of P. angulata's potential as an anti-lung cancer has not been widely informed, especially on the network pharmacology aspect of this plant's active compounds. This study reveals the prediction of the molecular mechanism of active compounds of P. angulata as anti-lung cancer using several tools including: Compound database retrieval with Knapsack and PubChem. Absorption Distribution Metabolism and Excretion (ADME) screening with SwissADME. Target protein identification with Gene Card, SwissTargetPrediction and Venny Diagram. Network pharmacology construction with String-DB and Cytoscape. Network pharmacology analysis using Gene Ontology (GO), and Cellular Component and Molecular Function. Based on the results of the analysis of P. angulata protein potential based on Maximal Clique Centrality (MCC) on CytoHubba in Cytoscape application, it shows that the Protein-protein Interaction (PPI) network has 10 main targets, namely ERBB2, KRAS, TP53, PTEN, CDKN2A, NRAS, PIK3CA, BRAF, NF1, and EGFR which interact with each other to regulate cell growth, differentiation, and survival. The results of this study can be concluded that the secondary metabolite compounds of P. angulata have the potential to control and alternative for lung cancer therapy.Keywords
This publication has 24 references indexed in Scilit:
- Anticancer Potential of β‐Carboline Alkaloids: An Updated Mechanistic OverviewChemistry & Biodiversity, 2024
- Physalin pool from Physalis angulata L. leaves and physalin D inhibit P2X7 receptor function in vitro and acute lung injury in vivoBiomedicine & Pharmacotherapy, 2021
- The P2X7 purinergic receptor: a potential therapeutic target for lung cancerJournal of Cancer Research and Clinical Oncology, 2020
- Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patientsInternational Journal of Cancer, 2019
- pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based SignaturesJournal of Medicinal Chemistry, 2015
- Inhibitory effects of Physalis angulata on tumor metastasis and angiogenesisJournal of Ethnopharmacology, 2011
- Physalis angulata induced G2/M phase arrest in human breast cancer cellsFood and Chemical Toxicology, 2006
- Physalins B, F and G, seco-steroids purified from Physalis angulata L., inhibit lymphocyte function and allogeneic transplant rejectionInternational Immunopharmacology, 2006
- Physalis peruviana extract induces apoptosis in human Hep G2 cells through CD95/CD95L system and the mitochondrial signaling transduction pathwayCancer Letters, 2004
- Antimycobacterial physalins from Physalis angulata L. (Solanaceae)Phytotherapy Research, 2002